[go: up one dir, main page]

WO2010142660A3 - Système d'administration de médicaments - Google Patents

Système d'administration de médicaments Download PDF

Info

Publication number
WO2010142660A3
WO2010142660A3 PCT/EP2010/057965 EP2010057965W WO2010142660A3 WO 2010142660 A3 WO2010142660 A3 WO 2010142660A3 EP 2010057965 W EP2010057965 W EP 2010057965W WO 2010142660 A3 WO2010142660 A3 WO 2010142660A3
Authority
WO
WIPO (PCT)
Prior art keywords
sirna
microparticles
useful
formulations
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2010/057965
Other languages
English (en)
Other versions
WO2010142660A2 (fr
Inventor
Michael Keller
Geoffrey Gogniat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of WO2010142660A2 publication Critical patent/WO2010142660A2/fr
Publication of WO2010142660A3 publication Critical patent/WO2010142660A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des formulations pharmaceutiquement actives constituée, d'une part de microparticules d'ARN interférent court de dimensions définies, d'autre part d'un polymère biodégradable hautement hydrophobe, et enfin d'un lipide cationique servant à la fois d'émulsifiant amphipathique et d'entité de liaison à l'ARN interférent court. L'invention concerne également des procédés de fabrication de ces microparticules. Ces formulations de microparticules, qui sont particulièrement adaptées à l'administration pulmonaire d'ARN interférent court, sont indiquées dans le cas d'un traitement d'affections pulmonaires.
PCT/EP2010/057965 2009-06-09 2010-06-08 Système d'administration de médicaments Ceased WO2010142660A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09162257.1 2009-06-09
EP09162257 2009-06-09

Publications (2)

Publication Number Publication Date
WO2010142660A2 WO2010142660A2 (fr) 2010-12-16
WO2010142660A3 true WO2010142660A3 (fr) 2011-08-25

Family

ID=41217671

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/057965 Ceased WO2010142660A2 (fr) 2009-06-09 2010-06-08 Système d'administration de médicaments

Country Status (1)

Country Link
WO (1) WO2010142660A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103796639B (zh) * 2011-07-06 2017-05-31 诺华股份有限公司 阳离子水包油乳液
CN102389756B (zh) * 2011-08-11 2014-01-01 长春金赛药业有限责任公司 复乳法制备微球的方法
DE102011114986A1 (de) * 2011-09-28 2013-03-28 Ethris Gmbh Sprühsystem
DE102017100317A1 (de) 2017-01-10 2018-07-12 Friedrich-Schiller-Universität Jena Nanostrukturiertes Trägersystem zum Gentransport
IT202100032393A1 (it) * 2021-12-23 2023-06-23 Torino Politecnico Metodo per la preparazione di nanoparticelle polimeriche ibride per il rilascio di farmaci oligonucleotidici nelle terapie farmacologiche a scopo rigenerativo, curativo e preventivo
WO2023172747A1 (fr) * 2022-03-11 2023-09-14 W. L. Gore & Associates, Inc. Particules bioabsorbables et procédé d'utilisation
CN117017946A (zh) * 2023-08-15 2023-11-10 福建医科大学 脂质聚合物杂化纳米粒、制备方法、药物组合物及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015816A1 (fr) * 2001-08-10 2003-02-27 Dynavax Technologies Corporation Preparations d'oligonucleotides immunomodulateurs et leurs procedes d'utilisation
WO2004026453A2 (fr) * 2002-09-06 2004-04-01 Genteric, Inc. Microcapsules et procedes d'utilisation associes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003015816A1 (fr) * 2001-08-10 2003-02-27 Dynavax Technologies Corporation Preparations d'oligonucleotides immunomodulateurs et leurs procedes d'utilisation
WO2004026453A2 (fr) * 2002-09-06 2004-04-01 Genteric, Inc. Microcapsules et procedes d'utilisation associes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TAHARA KOHEI ET AL: "[Development of gene delivery system using PLGA nanospheres]", YAKUGAKU ZASSHI : JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN OCT 2007, vol. 127, no. 10, October 2007 (2007-10-01), pages 1541 - 1548, XP002553274, ISSN: 0031-6903 *
TAKASHIMA ET AL: "Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 343, no. 1-2, 30 August 2007 (2007-08-30), pages 262 - 269, XP022223274, ISSN: 0378-5173 *

Also Published As

Publication number Publication date
WO2010142660A2 (fr) 2010-12-16

Similar Documents

Publication Publication Date Title
WO2010142660A3 (fr) Système d'administration de médicaments
WO2009129387A3 (fr) Lipides cationiques et utilisations associees
WO2011153493A3 (fr) Lipides biodégradables pour l'administration de principes actifs
WO2011022460A8 (fr) Nouveaux lipides cationiques avec différents groupes de tête pour délivrance d'oligonucléotide
WO2012042224A3 (fr) Composition pharmaceutique
WO2011043913A3 (fr) Nouveaux lipides cationiques à chaînes lipidiques courtes pour une administration d'oligonucléotides
WO2012003377A3 (fr) Procédé de préparation de tissu chorial et produits dérivés dudit tissu
WO2009012303A3 (fr) Nanoparticules thérapeutiques stables
WO2008030818A3 (fr) Nouvelles compositions de liposomes
WO2013052167A3 (fr) Nanoparticules encapsulées dans une membrane et leur procédé d'utilisation
WO2013105101A8 (fr) Nanoparticules lipidiques solides encapsulant un médicament hydrophile/amphiphile et leur procédé de préparation
WO2012103038A9 (fr) Compositions de nanoparticules, leurs formulations et leurs utilisations
WO2011053982A8 (fr) Compositions thérapeutiques à base de nucléases et méthodes
WO2009117130A3 (fr) Formulation à libération prolongée contenant une cire
WO2006099169A3 (fr) Nouvelles compositions de liposomes
WO2009138473A3 (fr) Libération intracellulaire d'anticorps
WO2008115469A3 (fr) Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
WO2010000877A3 (fr) Formulation à base de bisabolol et de [6]-paradol produisant un effet apaisant sur les irritations
WO2010021607A3 (fr) Préparation pharmaceutique
WO2010143969A3 (fr) Particules d'administration de médicament présentant une sensibilité acoustique comprenant de la phosphatidyléthanolamine formant des structures non lamellaires
SG194175A1 (en) Polymer conjugated prostaglandin analogues
WO2011163651A3 (fr) Procédés et compositions pour l'administration au snc de ss-galactocérébrosidase
WO2009053885A3 (fr) Procédés de préparation de microparticules de polymère
WO2012162439A3 (fr) Compositions comprenant de l'acide fusidique et leurs emballages
WO2010082220A3 (fr) Composition pharmaceutique à libération prolongée à base de quétiapine et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10724811

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10724811

Country of ref document: EP

Kind code of ref document: A2